Innovative Health Initiative / IMI AMR Accelerator / ND4BB
Capital Type
Public Private Partnership
Investment Size
Large consortium awards
Geographic Scope
Europe
Return Model
Non-Dilutive
Stage Focus
Preclinical, Translational, Clinical
Modality Focus
Antibiotics, Clinical infrastructure, Consortia
Overview
European public-private AMR infrastructure spanning the IMI ND4BB legacy and IHI-era AMR Accelerator efforts to move new antibacterial approaches forward.
Portfolio and Signals
Major European signal because these consortia specifically target resistant bacterial infections, clinical trial readiness, and collaborative drug-development infrastructure.
Access and Engagement
Access generally comes through consortium calls and European partnership proposals rather than direct company applications.
Notable AMR Examples / Programs
ND4BB legacy and AMR Accelerator consortia
Stay Updated
Stay connected so that you don't miss the latest AMR insights and updates.
